Research
Hormonal
GLP-1 receptor agonists (GLP-1RAs) and combination therapy led to a significant decrease in mean glycated hemoglobin (HbA1c) levels by −3.5% at 12 months compared to DPP-4 inhibitors.
Practitioners can consider GLP-1RAs and combination therapy as effective options for managing HbA1c in liver transplant recipients with diabetes.
StrongSupportsmedium confidence
Combination therapy remained significant when adjusted for DPP‐4 inhibitor treatment (−3.5%, 95% CI [−6.1, −0.95]; p = 0.0089) at 12 months.
Why this rating
The study is based on a retrospective analysis of prospectively collected data.
Source
<scp>Glucagon‐like peptide</scp> ‐1 receptor agonists and <scp>sodium‐glucose cotransporter</scp> ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients
Katina Zheng et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15769
cohort · n=362Cited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →